Bio Rad Laboratories Inc
General ticker "BIO" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $9.4B
Bio Rad Laboratories Inc follows the US Stock Market performance with the rate: 29.2%.
Estimated limits based on current volatility of 1.6%: low 323.15$, high 333.96$
Factors to consider:
- Company included in S&P500 list
- US accounted for 42.0% of revenue in the fiscal year ended 2023-12-31
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [247.89$, 400.18$]
- 2024-12-30 to 2025-12-30 estimated range: [239.46$, 386.99$]
Financial Metrics affecting the BIO estimates:
- Positive: Non-GAAP EPS, $ of 11.77 > 2.29
- Negative: negative Net income
- Positive: 9.05 < Operating profit margin, % of 12.65
- Positive: 2.35 < Operating cash flow per share per price, % of 4.15
Short-term BIO quotes
Long-term BIO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $2,922.55MM | $2,802.25MM | $2,671.26MM |
| Operating Expenses | $2,422.21MM | $2,319.63MM | $2,333.47MM |
| Operating Income | $500.34MM | $482.62MM | $337.80MM |
| Non-Operating Income | $4,948.72MM | $-5,186.89MM | $-1,187.90MM |
| Interest Expense | $1.55MM | $38.11MM | $49.44MM |
| R&D Expense | $271.66MM | $256.89MM | $226.93MM |
| Income(Loss) | $5,449.06MM | $-4,704.27MM | $-850.10MM |
| Taxes | $1,194.80MM | $-1,076.74MM | $-212.78MM |
| Profit(Loss) | $4,254.26MM | $-3,627.53MM | $-637.32MM |
| Stockholders Equity | $13,685.24MM | $9,615.25MM | $8,741.13MM |
| Inventory | $572.24MM | $719.32MM | $780.52MM |
| Assets | $17,799.39MM | $13,501.67MM | $12,299.07MM |
| Operating Cash Flow | $656.52MM | $194.45MM | $374.94MM |
| Capital expenditure | $120.80MM | $114.16MM | $156.68MM |
| Investing Cash Flow | $-784.44MM | $-1,207.59MM | $20.21MM |
| Financing Cash Flow | $-55.43MM | $973.58MM | $-425.65MM |
| Earnings Per Share* | $142.61 | $-121.79 | $-21.82 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.